{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T09:58:26Z","timestamp":1781517506251,"version":"3.54.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) have a direct cardiac effect that is likely to be independent of its glucose lowering renal effect. Previous research has shown that SGLT2-is mitigate heart failure and prevent arrhythmic cardiac death. Our objective is to determine whether SGLT-2is reduce atrial fibrillation (AF) in comparison to other second-to third-line antidiabetic drugs in type 2 diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>We conducted a population-based, new-user active comparator cohort study using data from the UK Clinical Practice Research Datalink. We identified a cohort of patients initiating a new antidiabetic drug class between January 2013 and September 2020. This cohort included patients initiating their first ever non-insulin antidiabetic drug, as well as those who switched to or added-on an antidiabetic drug class not previously used in their treatment history. Individuals with a diagnosis of AF or atrial flutter at any time before cohort entry were excluded. Cox regression analysis with time-dependent covariates was used to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs) of AF comparing SGLT-2-is with other second-line to third-line antidiabetic drugs. Stratified analyses were performed according to sex, diabetes duration (&amp;lt;5 or\u00a0\u2265\u00a05 years), body mass index (BMI), HbA1c, and presence of heart failure.<\/jats:p>\n                  <jats:p>The cohort comprised 142\u00a0447 patients. SGLT-2is were associated with a statistically significant reduced hazard of AF compared to other second-line to third-line antidiabetic drugs (adjusted HR: 0.77 [95% CI: 0.68\u20130.88]). This reduced risk was present in both sexes but was more prominently among women (adjusted HRwomen: 0.60 [95% CI: 0.45\u20130.79]; HRmen: 0.85 [95% CI: 0.73\u20130.98]; P-value interaction: 0.012). There was no evidence for effect modification when stratifying on duration of diabetes, BMI, HbA1c, or presence of heart failure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>SGLT-2is were associated with a reduced risk of AF in patients with type 2 diabetes compared to other second-line to third-line antidiabetic drugs. This reduced risk occurs in both sexes but more prominently among women.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvae022","type":"journal-article","created":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T07:47:31Z","timestamp":1711180051000},"page":"289-295","source":"Crossref","is-referenced-by-count":9,"title":["Sodium-glucose cotransporter-2 inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes: a population-based cohort study"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4381-0068","authenticated-orcid":false,"given":"Talip E","family":"Eroglu","sequence":"first","affiliation":[{"name":"Amsterdam UMC, Academic Medical Center, University of Amsterdam, Department of Experimental and Clinical Cardiology, Heart Centre, Amsterdam Cardiovascular Sciences , Meibergdreef 9, 1105 AZ Amsterdam , The Netherlands"},{"name":"Department of Cardiology, Copenhagen University Hospital\u2014Herlev and Gentofte , Gentofte Hospitalsvej 6, PO Box 635, DK-2900 Hellerup , Denmark"},{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University , 3584 CS Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9433-6119","authenticated-orcid":false,"given":"Ruben","family":"Coronel","sequence":"additional","affiliation":[{"name":"Amsterdam UMC, Academic Medical Center, University of Amsterdam, Department of Experimental and Clinical Cardiology, Heart Centre, Amsterdam Cardiovascular Sciences , Meibergdreef 9, 1105 AZ Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick C","family":"Souverein","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University , 3584 CS Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,22]]},"reference":[{"key":"2024071612155445000_bib1","doi-asserted-by":"crossref","first-page":"e192696","DOI":"10.1001\/jamanetworkopen.2019.2696","article-title":"Association of diabetes with all-cause and cause-specific mortality in Asia: a pooled analysis of more than 1 million participants","volume":"2","author":"Yang","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2024071612155445000_bib2","doi-asserted-by":"crossref","first-page":"e011295","DOI":"10.1161\/JAHA.118.011295","article-title":"Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults","volume":"8","author":"Raghavan","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2024071612155445000_bib3","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1001\/jama.1994.03510350050036","article-title":"Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study","volume":"271","author":"Benjamin","year":"1994","journal-title":"JAMA"},{"key":"2024071612155445000_bib4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1479164114561992","article-title":"Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences","volume":"12","author":"Gallo","year":"2015","journal-title":"Diabetes Vasc Dis Res"},{"key":"2024071612155445000_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-022-01480-1","article-title":"Direct cardiac effects of SGLT2 inhibitors","volume":"21","author":"Chen","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"2024071612155445000_bib6","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3389\/fphys.2020.00912","article-title":"Sodium-glucose cotransporter 2 inhibitors potentially prevent atrial fibrillation by ameliorating ion handling and mitochondrial dysfunction","volume":"11","author":"Peng","year":"2020","journal-title":"Front Physiol"},{"key":"2024071612155445000_bib7","doi-asserted-by":"crossref","first-page":"1011429","DOI":"10.3389\/fcvm.2022.1011429","article-title":"Benefits of SGLT2 inhibitors in arrhythmias","volume":"9","author":"Gao","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2024071612155445000_bib8","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3389\/fphys.2018.01575","article-title":"Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients","volume":"9","author":"Uthman","year":"2018","journal-title":"Frontiers Physiol"},{"key":"2024071612155445000_bib9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/ehjcvp\/pvad033","article-title":"Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus","volume":"9","author":"J\u00fal\u00edusd\u00f3ttir","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024071612155445000_bib10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/ehjcvp\/pvac043","article-title":"Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus","volume":"9","author":"Eroglu","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024071612155445000_bib11","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1093\/eurheartj\/ehab560","article-title":"Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF","volume":"42","author":"Curtain","year":"2021","journal-title":"Eur Heart J"},{"key":"2024071612155445000_bib12","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","article-title":"Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials","volume":"18","author":"Fernandes","year":"2021","journal-title":"Heart Rhythm"},{"key":"2024071612155445000_bib13","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.3390\/antiox10081166","article-title":"Emergence of SGLT2 inhibitors as powerful antioxidants in human diseases","volume":"10","author":"Tsai","year":"2021","journal-title":"Antioxidants"},{"key":"2024071612155445000_bib14","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ije\/dyv098","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD)","volume":"44","author":"Herrett","year":"2015","journal-title":"Int J Epidemiol"},{"key":"2024071612155445000_bib15","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jclinepi.2009.07.001","article-title":"Construction of drug treatment episodes from drug-dispensing histories is influenced by the gap length","volume":"63","author":"Gardarsdottir","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"2024071612155445000_bib16","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.4239\/wjd.v6.i13.1246","article-title":"Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research","volume":"6","author":"Leon","year":"2015","journal-title":"World J Diabetes"},{"key":"2024071612155445000_bib17","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.2337\/dc12-0788","article-title":"Metformin and the risk of cancer: time-related biases in observational studies","volume":"35","author":"Suissa","year":"2012","journal-title":"Diabetes Care"},{"key":"2024071612155445000_bib18","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4330\/wjc.v13.i10.585","article-title":"Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of cardiovascular outcome trials","volume":"13","author":"Patoulias","year":"2021","journal-title":"World J Cardiol"},{"key":"2024071612155445000_bib19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12933-017-0640-5","article-title":"Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fbrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan","volume":"16","author":"Chang","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"2024071612155445000_bib20","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2024071612155445000_bib21","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2024071612155445000_bib22","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.115.018614","article-title":"Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction","volume":"133","author":"Santhanakrishnan","year":"2016","journal-title":"Circulation"},{"key":"2024071612155445000_bib23","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1001\/jama.292.20.2471","article-title":"Obesity and the risk of new-onset atrial fibrillation","volume":"292","author":"Wang","year":"2004","journal-title":"JAMA"},{"key":"2024071612155445000_bib24","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"2024071612155445000_bib25","doi-asserted-by":"crossref","first-page":"e002183","DOI":"10.1161\/JAHA.115.002183","article-title":"Intracellular Na+ concentration ([Na+]i) is elevated in diabetic hearts due to enhanced Na+\u2014glucose cotransport","volume":"4","author":"Lambert","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"2024071612155445000_bib26","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nature12537","article-title":"Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation","volume":"502","author":"Erickson","year":"2013","journal-title":"Nature"},{"key":"2024071612155445000_bib27","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1161\/CIRCULATIONAHA.121.053350","article-title":"Cardiac late sodium channel current is a molecular target for the sodium\/glucose cotransporter 2 inhibitor empagliflozin","volume":"143","author":"Philippaert","year":"2021","journal-title":"Circulation"},{"key":"2024071612155445000_bib28","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3389\/fphar.2020.00413","article-title":"Late sodium current inhibitors as potential antiarrhythmic agents","volume":"11","author":"Horvath","year":"2020","journal-title":"Front Pharmacol"},{"key":"2024071612155445000_bib29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrcardio.2016.45","article-title":"Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis","volume":"13","author":"Ko","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"2024071612155445000_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-019-0964-4","article-title":"Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats","volume":"18","author":"Shao","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"2024071612155445000_bib31","first-page":"1","article-title":"Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis","volume":"20","author":"Li","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2024071612155445000_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-020-01162-w","article-title":"The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors","volume":"19","author":"Ling","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"2024071612155445000_bib33","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial","volume":"141","author":"Zelniker","year":"2020","journal-title":"Circulation"},{"key":"2024071612155445000_bib34","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2337\/dc22-0714","article-title":"Sodium\u2014glucose cotransporter 2 inhibitor treatment and risk of atrial fibrillation: scandinavian cohort study","volume":"46","author":"Engstr\u00f6m","year":"2023","journal-title":"Diabetes Care"},{"key":"2024071612155445000_bib35","doi-asserted-by":"crossref","first-page":"e2235995","DOI":"10.1001\/jamanetworkopen.2022.35995","article-title":"Association of sodium-glucose cotransporter-2 inhibitors with incident atrial fibrillation in older adults with type 2 diabetes","volume":"5","author":"Zhuo","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2024071612155445000_bib36","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10557-022-07319-x","article-title":"Comparison of sodium-glucose cotransporter-2 inhibitor and dipeptidyl peptidase-4 inhibitor on the risks of new-onset atrial fibrillation, stroke and mortality in diabetic patients: a propensity score-matched study in Hong Kong","volume":"37","author":"Lee","year":"2023","journal-title":"Cardiovasc Drugs Ther"},{"key":"2024071612155445000_bib37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12933-023-01772-0","article-title":"Risks of stroke, its subtypes and atrial fbrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong","volume":"22","author":"Lui","year":"2023","journal-title":"Cardiovasc Diabetol"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvae022\/57796703\/pvae022.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/4\/289\/58555331\/pvae022.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/4\/289\/58555331\/pvae022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T12:16:41Z","timestamp":1721132201000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/10\/4\/289\/7633947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,22]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,3,22]]},"published-print":{"date-parts":[[2024,7,16]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvae022","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,3,22]]}}}